ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of ESPRIT was to compare the efficacy and safety of mild anticoagulation or a combination treatment of aspirin and dipyridamole with the efficacy and safety of treatment with aspirin alone after cerebral ischemia of arterial origin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UMC Utrecht
• Treatments: Aspirin; Dipyridamole

Criteria

Inclusion Criteria:

• Patients presenting in the participating hospitals with a TIA or non-disabling stroke of atherosclerotic origin

• Randomisation within 6 months after the TIA or minor stroke

• Modified Rankin scale of 3 or less

Exclusion Criteria:

• (Contra)indication to, or intolerance to, anticoagulants, dipyridamole, or aspirin

• Disease expected to cause death within weeks or months

• Source of embolism in the heart

• Moderate or severe ischemic damage to the white matter of the brain (leukoaraiosis)

• Anemia, polycythemia, thrombocytosis, or thrombocytopenia

• Planned carotid endarterectomy

• Intracranial bleeding or cerebral tumour

• TIA or stroke caused by vasculitis, migraine, or dissection

• Severe hypertension

• Liver failure

• Pregnancy

• Chronic alcohol abuse